Document is current
Any future updates will be listed below
-
Authors
Bilen, Mehmet A. https://orcid.org/0000-0003-4003-1103
Vo, BaoHan T. https://orcid.org/0009-0009-5179-1889
Liu, Yuan https://orcid.org/0000-0001-8926-3058
Greenwald, Rachel https://orcid.org/0000-0003-3139-5079
Davarpanah, Amir H.
McGuire, Donald https://orcid.org/0000-0002-3742-9594
Shiradkar, Rakesh
Li, Liping https://orcid.org/0009-0009-9064-2456
Midya, Adhishek
Nazha, Bassel
Brown, Jacqueline T.
Williams, Sierra
Session, Wilena
Russler, Greta
Caulfield, Sarah
Joshi, Shreyas S.
Narayan, Vikram M. https://orcid.org/0000-0003-3731-4209
Filson, Christopher P.
Ogan, Kenneth
Kucuk, Omer
Carthon, Bradley Curtis
Del Balzo, Luke
Cohen, Athena
Boyanton, Adriana
Prokhnevska, Nataliya
Cardenas, Maria Andrea https://orcid.org/0000-0002-8566-9576
Sobierajska, Ewelina
Jansen, Caroline S. https://orcid.org/0000-0001-9128-2004
Patil, Dattatraya H.
Nicaise, Edouard
Osunkoya, Adeboye O. https://orcid.org/0000-0001-5712-8134
Kissick, Haydn T. https://orcid.org/0000-0001-7624-5598
Master, Viraj A. https://orcid.org/0000-0002-7251-142X
- License Information
-
More Information
Article History
Received: 20 May 2024
Accepted: 29 January 2025
First Online: 27 February 2025
Competing interests
: M.A.B. has acted as a paid consultant for and/or as a member of the advisory boards of Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen and Sanofi and his institution has received grants from Merck, Xencor, Bayer, Bristol Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Exelixis, Nikang, Loxo Oncology, Ambrx, Regeneron, Acrivon Therapeutics, Amgen, Genome & Company, AAA, Peloton Therapeutics and Pfizer for work performed outside of the current study. The other authors declare no competing interests.
